Capstone Investment Advisors’s Trillium Therapeutics Inc. TRIL Stock Holding History

Capstone Investment Advisors’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-115,451	Closed	-$2.03M	–	2181
2021 Q3	$2.03M	Buy	+115,451	New	+$1.35M	﹤0.01%	1185

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Capstone Investment Advisors's TRIL Position: Q4 2021 in Review

Capstone Investment Advisors sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 115,451 shares — an estimated $2.03M sold.

Capstone Investment Advisors first reported a position in TRIL in Q3 2021 and held it in 1 quarter. The position peaked at $2.03M in Q3 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

Capstone Investment Advisors reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
Capstone Investment Advisors sold 115,451 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $2.03M.
Capstone Investment Advisors first reported a position in Trillium Therapeutics Inc. in Q3 2021 and held it in 1 quarter.
Capstone Investment Advisors's Trillium Therapeutics Inc. position peaked at $2.03M in Q3 2021.
2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on Capstone Investment Advisors's 13F filing for Q4 2021, filed 11 Feb 2022.